PGV-1 permanently arrests HepG2 cells in M phase and inhibits liver carcinogenesis in DMH-induced rats
Penulis/Author
Dhania Novitasari (1); Jun-Ya Kato (2); Dr. apt. Muthi' Ikawati, M.Sc. (3); Dr. apt. Dyaningtyas Dewi Pamungkas Putri, M.Sc. (4); Febri Wulandari (5); drh. Sitarina Widyarini, M.P., Ph.D. (6); UMMI MARYAM ZULFIN (7); Dhiya Ulhaq Salsabila (8); Prof. Dr. apt. Edy Meiyanto, M.Si. (9)
Tanggal/Date
2023
Kata Kunci/Keyword
Abstrak/Abstract
Pentagamavunone-1 (PGV-1) has been reported to eliminate cancer cell progression in the breast, blood, and colon.
The current approach evaluates its antiproliferative effects and cellular activity against hepatocellular carcinoma cells
(HCC). We used the HepG2 cells as an in vitro model for HCC, and PGV-1 was tested for its effects on cell viability,
cell cycle modulation, senescence induction, reactive oxygen species (ROS) generation, and cell migration. Moreover,
the ability of PGV-1 to prevent liver carcinogenesis was tested in 1,2-dimethylhydrazine- (DMH-) induced rats. PGV-1
irreversibly inhibited cell proliferation via mitotic arrest and cellular senescence. The ROS production was enhanced
during the earlier hours of incubation with the compound. Later, PGV-1 significantly delayed the HepG2 cell migration
and invasion. Furthermore, PGV-1 prevented steatohepatitis upon DMH administration and drastically reduced the
Ki-67 expression in DMH-induced rat liver, indicating its ability to suppress aberrant liver cell proliferation. These
findings add to the evidence that PGV-1 could be further developed pharmaceutically as a candidate for cancer therapy
with a specific target on mitosis.
